Your browser doesn't support javascript.
loading
Risk of end-stage renal disease in patients with early-onset lupus nephritis: A population-based cohort study.
Cho, Soo-Kyung; Kim, Hyoungyoung; Han, Jung-Yong; Jeon, Yena; Jung, Sun-Young; Jang, Eun Jin; Sung, Yoon-Kyoung.
Affiliation
  • Cho SK; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea; Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea.
  • Kim H; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea; Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea.
  • Han JY; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea; Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea.
  • Jeon Y; Department of Statistics, Kyungpook National University, Daegu, Republic of Korea.
  • Jung SY; College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Jang EJ; Department of Information Statistics, Andong National University, Andong, Republic of Korea.
  • Sung YK; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea; Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea. Electronic address: sungyk@hanyang.ac.kr.
Semin Arthritis Rheum ; 63: 152308, 2023 12.
Article in En | MEDLINE | ID: mdl-37976812
ABSTRACT

OBJECTIVE:

To compare the risk of end-stage renal disease (ESRD) between patients with early-onset lupus nephritis (EOLN) and those with delayed-onset LN (DOLN).

METHODS:

This retrospective study of incident cases of systemic lupus erythematosus (SLE) used nationwide Korean claims databases and data from 2008 through 2018. We divided LN patients into two groups the EOLN group (with LN onset within 12 months of SLE diagnoses) and the DOLN group (with LN onset later than 12 months after SLE diagnoses). Patients were observed from the date of LN diagnosis to the development of ESRD, death, or the last follow-up. Cox proportional hazards modeling was used to predict hazard ratios (HRs) for progression to ESRD with death as a competing risk.

RESULTS:

We identified 3779 incident SLE patients who developed LN during follow-up 60 % (n = 2281) had EOLN, and 40 % (n = 1489) had DOLN. Sixty-nine patients with EOLN (3.0 %) and 29 patients with DOLN (1.9 %) progressed to ESRD. After adjusting for confounders, the ESRD risk associated with EOLN was comparable to the risk associated with DOLN (HR 1.10, 95 % confidence interval [CI] 0.57 to 2.11). In the subgroup of patients on aggressive immunosuppressive therapy (670 with EOLN and 179 with DOLN), the ESRD risk was higher in the DOLN group (HR 2.6, 95 % CI 1.11 to 6.10).

CONCLUSION:

The risk of ESRD was comparable between patients with EOLN and DOLN. However, among patients on aggressive immunosuppressive therapy, compared with EOLN, DOLN was associated with a higher risk of progression to ESRD.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Nephritis / Kidney Failure, Chronic / Lupus Erythematosus, Systemic Limits: Humans Language: En Journal: Semin Arthritis Rheum Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Nephritis / Kidney Failure, Chronic / Lupus Erythematosus, Systemic Limits: Humans Language: En Journal: Semin Arthritis Rheum Year: 2023 Document type: Article